Cardiol Therapeutics (CRDL) Receivables - Other (2020 - 2026)

Cardiol Therapeutics has reported Receivables - Other for 7 years, with the latest figure at -$72309.5 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 995.05% year-over-year to -$72309.5; the trailing twelve-month figure through Mar 2026 stood at -$72309.5 (down 995.05% YoY), and the FY2025 full-year result was $122240.3, down 34.64% from the prior year.
• Receivables - Other for Q1 2026 stood at -$72309.5, down from $122240.3 in the prior quarter.
• The five-year high for Receivables - Other was $199111.7 in Q4 2022, with the low at -$72309.5 in Q1 2026.
• Historically, Receivables - Other has averaged $53450.1 across 5 years, with a median of $44335.2 in 2023.
• Annual changes were most pronounced in 2025 — Receivables - Other surged 441.49% — and 2026, when it tumbled 995.05%.
• Cardiol Therapeutics' Receivables - Other stood at $199111.7 in 2022, then sank by 49.41% to $100724.7 in 2023, then jumped by 85.67% to $187019.2 in 2024, then slumped by 34.64% to $122240.3 in 2025, then slumped by 159.15% to -$72309.5 in 2026.
• The last three Receivables - Other figures came in at -$72309.5 (Q1 2026), $122240.3 (Q4 2025), and $115088.8 (Q3 2025), per Business Quant data.